EXCLUSIVE AUDIO SERIES: Atopic Dermatitis Advisor
After reviewing notable safety considerations for systemic and topical Janus kinase inhibitors for patients with atopic dermatitis, Nicole Keeter, PA-C, describes steps she has taken to become more comfortable prescribing these agents to her patients with AD and discusses important tips for counseling these patients on adverse events and black box warnings.
Current issue
NP+PA Perspectives in Dermatology: March 2023
J Clin Aesthet Dermatol. 2023;16(3 Suppl 1) NP+PA Perspectives in Dermatology: March […]
The Psoriasis Decision Tree
Reproduced with permission: J Clin Aesthet Dermatol. 2021;14(4):14–22. by George Monks, MD; […]
J Clin Aesthet Dermatol. 2023;16(3 Suppl 1):S29–S33 by Rohan R. Shah, BA; […]
J Clin Aesthet Dermatol. 2023;16(3 Suppl 1):S41–S46. by Nourhan Anis, MD; Nagwa […]
Special Bonus Issue—Dermatology NP & PA Workforce Survey: Practice Characteristics and Compensation
J Clin Aesthet Dermatol. 2023;16(2 Suppl 1) Special Bonus Issue—Dermatology NP & […]
Dermatological Conditions in Skin of Color— Physiological Nuances in Skin of Color and Their Clinical Implications
J Clin Aesthet Dermatol. 2023;16(2 Suppl 1):S12–S13 by Archana M. Sangha, MMS, […]
Incorporating JAK Inhibitors into Clinical Practice for the Treatment of Atopic Dermatitis—Safety Considerations
J Clin Aesthet Dermatol 2023;16(2 Suppl 1):14 An interview with Nicole Keeter […]